Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 4
2007 1
2008 7
2009 4
2010 5
2011 7
2012 6
2013 5
2014 6
2015 9
2016 7
2017 10
2018 10
2019 8
2020 6
2021 10
2022 16
2023 9
2024 12
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE. Bensch F, et al. Among authors: brouwers ah. Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26. Nat Med. 2018. PMID: 30478423 Clinical Trial.
Molecular imaging to support cancer immunotherapy.
van de Donk PP, Oosting SF, Knapen DG, van der Wekken AJ, Brouwers AH, Lub-de Hooge MN, de Groot DA, de Vries EG. van de Donk PP, et al. Among authors: brouwers ah. J Immunother Cancer. 2022 Aug;10(8):e004949. doi: 10.1136/jitc-2022-004949. J Immunother Cancer. 2022. PMID: 35922089 Free PMC article. Review.
Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT.
Boss M, Eriksson O, Mikkola K, Eek A, Brom M, Buitinga M, Brouwers AH, Velikyan I, Waser B, Kauhanen S, Solin O, Marciniak C, Eriksson B, Reubi JC, Aveline C, Wild D, Pattou F, Talbot JN, Hofland J, Sundin A, Nuutila P, Hermans J, Gotthardt M. Boss M, et al. Among authors: brouwers ah. J Nucl Med. 2024 Dec 3;65(12):1959-1964. doi: 10.2967/jnumed.124.268158. J Nucl Med. 2024. PMID: 39419553 Free PMC article.
Theranostics Using Antibodies and Antibody-Related Therapeutics.
Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, Lub-de Hooge MN, Brouwers AH, de Vries EGE. Moek KL, et al. Among authors: brouwers ah. J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S. doi: 10.2967/jnumed.116.186940. J Nucl Med. 2017. PMID: 28864618 Free article. Review.
Update on the Role of [18F]FDOPA PET/CT.
Stormezand GN, de Meyer E, Koopmans KP, Brouwers AH, Luurtsema G, Dierckx RAJO. Stormezand GN, et al. Among authors: brouwers ah. Semin Nucl Med. 2024 Nov;54(6):845-855. doi: 10.1053/j.semnuclmed.2024.09.004. Epub 2024 Oct 9. Semin Nucl Med. 2024. PMID: 39384519 Free article.
Molecular Imaging in Cancer Drug Development.
Waaijer SJH, Kok IC, Eisses B, Schröder CP, Jalving M, Brouwers AH, Lub-de Hooge MN, de Vries EGE. Waaijer SJH, et al. Among authors: brouwers ah. J Nucl Med. 2018 May;59(5):726-732. doi: 10.2967/jnumed.116.188045. Epub 2018 Jan 25. J Nucl Med. 2018. PMID: 29371402 Free article. Review.
Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.
Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, Oosting SF, Jalving M, Timens W, Brouwers AH, Kwee TC, Gietema JA, Fehrmann RSN, Fine BM, Sanabria Bohórquez SM, Yadav M, Koeppen H, Jing J, Guelman S, Lin MT, Mamounas MJ, Eastham JR, Kimes PK, Williams SP, Ungewickell A, de Groot DJA, de Vries EGE. Kist de Ruijter L, et al. Among authors: brouwers ah. Nat Med. 2022 Dec;28(12):2601-2610. doi: 10.1038/s41591-022-02084-8. Epub 2022 Dec 5. Nat Med. 2022. PMID: 36471036 Free PMC article. Clinical Trial.
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
Eisses B, van Geel JJL, Brouwers AH, Bensch F, Elias SG, Kuip EJM, Jager A, van der Vegt B, Lub-de Hooge MN, Emmering J, Arens AIJ, Zwezerijnen GJC, Vugts DJ, Menke-van der Houven van Oordt CW, de Vries EGE, Schröder CP. Eisses B, et al. Among authors: brouwers ah. J Nucl Med. 2024 Oct 1;65(10):1540-1547. doi: 10.2967/jnumed.124.267636. J Nucl Med. 2024. PMID: 39237347
Advances and challenges in immunoPET methodology.
Mohr P, van Sluis J, Lub-de Hooge MN, Lammertsma AA, Brouwers AH, Tsoumpas C. Mohr P, et al. Among authors: brouwers ah. Front Nucl Med. 2024 Feb 19;4:1360710. doi: 10.3389/fnume.2024.1360710. eCollection 2024. Front Nucl Med. 2024. PMID: 39355220 Free PMC article. Review.
137 results